I NTRO D U CTlO N
In the last decade, considerable interest was focused on the concept of human neutrophils as mediators of tissue injury during inflammatory diseases, ranging from chronic obstructive pulmonary disease, adult respiratory distress syndromes and autoimmune arthritides to neutrophilic dermatoses, inflammatory bowel diseases and immune vasculitides [l, 21 . The growing knowledge of neutrophil physiopathology has recently led to the identification of a major histotoxic pathway. Neutrophils, recruited at sites of inflammation, generate superoxide anion (O;'), which rapidly dismutates to hydrogen peroxide (H202) [3, 4] . In turn, H,O, is transformed into hypochlorous acid (HOC1) by neutrophil myeloperoxidase (MPO) [3, 51. As a consequence of its extremely high reactivity [ S ] , HOCl represents the most toxic oxidant generated by neutrophils, also capable of reacting with various glycoproteins such as a,-antitrypsin (AT) [3, 5, 61 . This glycoprotein, synthesized by hepatocytes and macrophages [7] , belongs to the system of acutephase proteins [S] , diffuses into inflamed tissue from the circulation easily [S] and represents the specific inhibitor of the major neutrophil proteolytic enzyme, elastase [7, 81. Owing to the capacity of HOCl to react and oxidatively inactivate AT [3, 81, elastase can escape regulation by AT and digest important connective tissue components such as elastin, certain types of collagen, fibronectin, laminin and the proteic domains of proteoglycans [7, 81.
Therefore, oxidative attack and elastolytic injury of inflamed tissue by neutrophils appear to be interlinked events, HOCl playing a pivotal role in these processes.
At present, non-steroidal anti-inflammatory drugs (NSAIDs) represent the major candidates for controlling neutrophil-mediated tissue injury. Although numerous studies have tested the effects of NSAIDs on various neutrophil functions (reviewed in [S]), the possibility that they can interfere with the aforementioned histotoxic pathway has not been experimentally tested. Recently, we found that the NSAID nimesulide [lo, 111 is particularly efficient in reducing HOCl availability in the neutrophil surroundings, in turn preventing AT inactivation [l2]. Consequently, we planned the present study to test the effects of various NSAIDs on the neutrophil HOCI-dependent AT inactivation. Nimesulide, sodium salicylate, acetylsalicylic acid, ibuprofen, naproxen and tenoxicam were tested in parallel assays. We also studied dapsone and sulphapyridine, reported to have beneficial effects in diseases characterized by neutrophilic inflammation [13] .
MATERIALS A N D METHODS

Media and reagents
Hanks' balanced saline solution containing 1 mg/ml glucose and without Phenol Red (HBSS; ICN Biomed, Milan, Italy) was used as incubation medium. Taurine, L-methionine, sodium benzoate, sodium azide, o-dianisidine, mannitol, superoxide dismutase type I (bovine blood) and ferricytochrome c type VI (horse heart) were purchased from Sigma (St Louis, MO, U.S.A.). a,-Antitrypsin (AT; lot 286029), porcine pancreatic elastase (PPE, lot 801800) and N-succinyl-( 1-alanyl),-p-nitroanilide (lot 5 10008) were purchased from Calbiochem (San Diego, CA, U.S.A.). Heparin (Liquemin) was purchased from Roche (Milan, Italy) and FicollHypaque from Nyegaard (Oslo, Norway). Phorbol 12-myristate 13-acetate (PMA; Sigma), stored at -20°C as stock solution of 2mg/ml in dimethyl sulphoxide (DMSO; C. Erba, Milan, Italy) was diluted in medium and used at the final concentration of 10 ng/ml. The reagent 5-mercapto-2-nitrobenzoic acid was prepared by reducing 3-3'-dithiobis [6-nitrobenzoic] acid (Sigma) [ 
141.
Hypochlorous acid (HOCl) was generated by dissolving sodium hypochlorite (BDH, Poole, U.K.) into solution buffered at pH 7.4 [12] . Sodium salicylate, acetylsalicylic acid, ibuprofen, naproxen, tenoxicam, dapsone, sulphapyridine, sulphanilamide and sulphamethoxazole were purchased from Sigma. Nimesulide was a gift from LPB Institute (Milan, Italy). Other reagent-grade compounds were used as obtained from commercial suppliers.
Neutrophils
Heparinized (heparin 10 units/ml) venous blood was obtained from healthy male volunteers after informed consent was obtained. 
Inactivation of AT by neutrophils
The inactivation of AT by neutrophils was accomplished using 2.5 x lo6 neutrophils, 125pg of AT and 10ng/ml PMA in a final volume of 0.25ml.
The experiments were carried out in the absence and presence of acetylsalicylic acid, sodium salicylate, ibuprofen, naproxen, tenoxicam, dapsone, sulphapyridine, sulphanilamide and sulphamethoxazole at final concentrations of 10, 20, 50, lOOpmol/l. Moreover, other experiments were carried out in the presence of 1 mmol/l azide, 20 mmol/l methionine or taurine and 20 mmol/l mannitol or benzoate. The incubations (30min, 37°C) were in Falcon Plastic tubes (10 x 100mm, Falcon Plastic, Oxnard, CA, U.S.A.). At the end of the incubation period, methionine (500 nmol) was added to each tube to quench residual oxidants and the cell-free supernatants were isolated by centrifugation (500g for 5 min at 4°C). The AT activity was then determined in the supernatants.
Assay of AT activity
The capacity of AT to inhibit PPE, i.e. the elastase inhibitory capacity (EIC) was used as a measure of active AT. The method was a modification of the standard spectrophotometric assay [12] . Briefly, 40 pl of supernatant containing AT and 20 pl of 37 units/ml PPE were mixed with 1OOpl of 0.2mol/l Tris-HCI buffer (pH 8.0) in a microtitre tray (Titertek microtitration equipment, Flow). The tests were carried out in triplicate. The microplate was agitated for 30min (37°C) in a microplate spectrophotometer reader (Titertek Twinreader Plus, Flow). Then 20pl of the reaction mixture was transferred into the wells of another microtitre tray containing 230 pl of the PPE substrate C6.6 mmol/l N-succinyl( 1 -alanyl),-p-nitroanilide in 0.05 mol/l Tris-HC1, pH 8.0, containing 0.3% DMSO]. The tray was agitated for 10s (25"C), the absorbance at a wavelength of 405 nm was read immediately and again every minute for 5min, and the change in absorbance was calculated. The percentage loss of EIC was calculated by comparing the ability of equal amounts of control and test samples of AT to suppress PPE activity. The reproducibility of the assay, expressed as coefficient of variation, was 11.02% ( n = 10).
Hypochlorous acid assay
The generation of HOCl by neutrophils, incubated in the absence or presence of the aforementioned drugs (10, 20, 50 , lOOpmol/l), was measured by the taurine trapping technique [l5], as previously described [ 141. The incubations were carried out using 5 x 10' neutrophils and 10ng/ml PMA in a final volume of 1 ml containing 20mmol/l taurine. At the end of the incubation period (60min, 37°C) the amount of HOCl trapped by taurine (yielding taurine monochloramine) in the cell-free supernatants was determined by measuring spectrophotometrically (absorbance =412 nm, E = 1.36 x 
Other assay
To test the capacity of dapsone, nimesulide, sulphanilamide and sulphapyridine to compete with AT for reagent HOCl, each drug (1 mmol/l) was mixed with AT (33.3pg) before the addition of reagent HOCl (30pmol/l). The final volume of the mixture was 200 pl. After incubation (1 5 min), the percentage EIC of AT was measured as described above. Experiments were carried out in triplicate. The generation of hydroxyl (.OH) radicals by neubrophils was studied by a deoxyribose oxidation spectiofluorimetric assay [16] . The production of superoxide anion (0;') by neutrophils was studied by using a modification of the method of Babior et al.
[17], p s previously described [16] . The MPO activity rcdeased by neutrophils was determined by an o-diaaisidine method, as described previously ~141.
Statistical analysis
The results were expressed as means+ 1 SD. The effect of drugs on the EIC of AT incubated with neutrophils, and their ability to reduce the recovery of HOCl from neutrophils, were analysed by calculating the inhibitory dose 50% (ID5,,) for each drug. In this regard, differences among drugs were tested by the non-parametric Kruskal-Wallis test. The existence of a monotonic trend between the drugdependent prevention of AT inactivation by neutrophils and the drug-induced reduction of HOCl recovery from neutrophils was tested for each drug using the Kendall z. Regression parameters were estimates using the non-parametric Theil procedure. Differences, if any, between drugs were determined by the non-parametric co-variance analysis of Theil.
RESU LTS
When exposed to 2.5 x lo6 stimulated neutrophils, 125pg of AT was completely inactivated during a 30-min incubation period. Conversely, resting neutrophils, i.e. cells incubated in absence of PMA, were completely ineffective. As summarized in Fig. 1, 4 of 10 drugs prevented the AT inactivation by neutrophils (dapsone, nimesulide, sulphanilamide and sulphapyridine at the concentration of 50pmol/l). In a parallel series of experiments, various chemicals were used as investigative probes. Azide (1 mmol/l, MPO inhibitor), methionine and taurine (20 mmol/l, HOCl inactivators) prevented AT inactivation almost completely (EIC of AT incubated with neutrophils in the presence of these compounds > 92%). Inactivators of .OH radicals such as mannitol and benzoate (20 mmol/l) were ineffective (EIC of AT<2%), consistent with the incapacity of neutrophils to generate these oxidants (.OH radicals could not be detected, using the deoxyribose oxidation assay). Since these data point towards the intervention of HOC1, a set of experiments was planned to test in parallel assays both the ability of drugs to prevent AT inactivation by neutrophils and the ability to reduce the recovery of HOCl from neutrophils, as measured by the taurinetrapping technique. The four drugs inhibiting the inactivation of AT by neutrophils (Fig. 1) were found to exert their action in a dose-dependent manner (Fig. 2) . The activity of sulphanilamide was significantly lower than that of the other three drugs (legend to Fig. 2) . Moreover, these drugs were found to reduce the HOCl recovery from neutrophils in a dose-dependent manner (Fig. 3) . In this regard, differences among drugs were not significant (legend to Fig. 3 ). As summarized in Table 1 , negative trends were found between the capacity of each drug to preserve the EIC of neutrophil-exposed AT and the HOCl recovery from neutrophils in the presence of drugs. The slope obtained with sulphanilamide was significantly lower than that calculated for the other drugs (Table 1) . With the exception of sulphamethoxazole, the remaining drugs incapable of preventing AT inactivation by neutrophils (Fig. 1) did not affect the HOCl recovery from neutrophils (data not shown). Although incapable of preventing AT inactivation, sulphamethoxazole reduced HOCl recovery from neutrophils in a dose-dependent manner up to approximately 40% inhibition at lOOpmol/l (data not shown). Under the present setting, drugs did not affect oxidant production by neutrophils, as judged by measuring 0;' generation (0;' generation 131.6+ 11.7nm0l30rnin-~ cells, mean) 1 SD, n=6). Moreover, they did not inhibit the release of MPO by neutrophils (MPO release 1.38850.121 m-units 60min-' cells, mean 5 1 SD, n = 5). Finally, they did not interfere with the activity of MPO (data not shown). In contrast, drugs inhibiting the inactivation of AT by neutrophils were found to prevent AT inactivation by reagent HOCl as well (Fig. 4) .
DISCUSSION
The present results show that certain drugs (dapsone, nimesulide, sulphapyridine, sulphanilamide), used at concentrations achievable in vivo [lo, 201 , are capable of protecting AT from inactivation by neutrophils. These drugs act primarily by trapping neutrophil-derived HOCl before its collision with AT molecules. Several findings are consistent with this view. First, well-known inhibitors of the HOClgenerating MPO system prevented AT inactivation by neutrophils. This suggests that neutrophils preferentially use HOCl for suppressing AT function. This conclusion is in agreement with the results obtained by other authors [S, 213. Second, dapsone, nimesulide, sulphapyridine and sulphanilamide caused a dose-dependent inhibition of HOCl recovery from neutrophils. As these drugs did not affect the oxidative burst and the MPO release or function, they appear to act by direct scavenging of released HOCl rather than by inhibition of HOCl production. Nevertheless, when tested with neutrophils challenged with opsonized zymosan particles, nimesulide at high concentrations (100 pmol/l) can also reduce oxygen consumption and 0;' generation, and thus production of HOCl [22] . Third, for each of the aforementioned drugs, the ability to lower the HOCl recovery from neutrophils correlates significantly with the capacity to prevent AT inactivation. Although the four drugs were equally effective in inhibiting HOCl recovery, the capacity of sulphanilamide to protect AT from neutrophilmediated inactivation was significantly lower than that of the other three drugs. This probably reflects a relatively low efficiency of sulphanilamide in competing with AT for neutrophil-derived HOCl. Consistent with this possibility, another drug, i.e. sulphamethoxazole, was found to be incapable of protecting AT from neutrophil inactivation at a concentration causing approximately 40% inhibition of HOCl recovery. Fourth, the four drugs inhibiting AT inactivation by neutrophils prevented AT inactivation by reagent HOCl as well. This is consistent with the possibility that they can actually act by directly inachwting neutrophil-derived HOCI. The different efficimcy of the four drugs in protecting AT in the neutrophil system compared with the reagent HOCl system is likely to reflect different kinetics of HOCl delivery, i.e. neutrophil generation of HOCl as a flux versus direct bolus of HOCl in the cell-free system.
Owing to the potent oxidative properties of HOCl [S] , and taking into account the fact that AT is the natural inhibitor of neutrophil elastase [7, 81, the present results suggest that these drugs have the potential to limit both the oxidative and the elastolytic histotoxicity of activated neutrophils. In other words, these drugs can counteract the oxidantantioxidant and the protease-antiprotease imbalances which are crucial for the pathogenesis of tissue injury at sites of neutrophilic inflammation [3, 61. On the other hand, the control of elastase activity by rescued AT can be expected to substantially contribute to the known anti-inflammatory properties of these drugs. In fact, neutrophil elastase promotes microvascular permeability changes leading to plasma exudation [23] , favours the generation of kinins and the activation of complement by digesting the C1-inhibitor [S] and induces the production of the neutrophil chemotaxin interleukin 8 by certain tissue cells [24] . It is, however, of note that these drugs also exert other anti-inflammatory effects upon neutrophil function, such as inhibition of adhesion and platelet-activating factor (PAF) production [25, 261. The properties discussed above characterize a minority of the drugs studied. These properties are likely to reflect a particular affinity of these compounds for HOCl, at least in part independently on the presence of -NH, groups able to react easily with HOCl [S]. In fact, although the five compounds shown in Fig. 5 are endowed with -NH, groups, they have different abilities to prevent AT inactivation. Sulphamethoxazole is ineffective, and sulphanilamide is significantly less efficient than dapsone, nimesulide and sulphapyridine, which are equally active. In conclusion, the bulk of our data suggest some general and pertinent comments. First, the drugs proved to be active in the present systems (dapsone, nimesulide and sulphapyridine) have structural similarities and/or are derivatives of sulphanilamide [20] (Fig. 5) . Second, these drugs are particularly prone to react with neutrophilderived HOCl, preventing its toxicity. Third, they have been reported to have beneficial effects in conditions characterized by neutrophil inflammation [9, 11, 271 . Therefore, on the basis of these chemical, pharmacodynamic and clinical criteria, sulphanilamide-related (i.e. sulphonamide) antiinflammatory agents [28] appear as a well-defined group of drugs to be considered for planning rational therapeutic strategies to control tissue injury during neutrophilic inflammation. Also, this group of drugs may be a starting point for the development of new compounds to counteract deleterious effects of activated neutrophils.
